E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Aneurysmal subarachnoid haemorrhage Cerebral vasospasm Ischaemic stroke |
|
E.1.1.1 | Medical condition in easily understood language |
Stroke/permanent disability caused by reduced reduced blood flow to the brain, which is due to the narrowing of brain blood vessels after a specific type of brain bleeding (subarachnoid hemorrhage). |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10047164 |
E.1.2 | Term | Vasospasm cerebral |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10061256 |
E.1.2 | Term | Ischaemic stroke |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10055845 |
E.1.2 | Term | Haemorrhage subarachnoid |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Does donepezil improve brain blood flow after brain bleeding from aneurysms (subarachnoid haemorrhage)? |
|
E.2.2 | Secondary objectives of the trial |
Is donepezil safe and well tolerated in patients with acute brain bleeding (subarachnoid haemorrhage)? |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Patients aged 18-85 admitted to St George's Hospital neurosurgical service with confirmed aneurysmal subarachnoid haemorrhage (brain bleeding from an aneurysm). 2. Amount of blood: Fisher score = 2 or greater (blood load on CT scan) 3. Able to be enroled within 12-72 hours of brain bleeding symptom onset. 4. Index aneurysm suitable for endovascular occlusion (coiling) |
|
E.4 | Principal exclusion criteria |
1. Allergy to donepezil or other piperidine derivatives. 2. Pregnancy. 3. Lactating or breast feeding women 4. Male or female participants that are unwilling to use an effective method of birth control (hormonal or barrier method of birth control; abstinence from time consent is signed until 6 weeks after the last dose of Donepezil 5. Known dementia. 6. Severe hepatic impairment (Child-Pugh Class C) 7. Patients with ‘sick sinus syndrome’ or other supraventricular cardiac conduction conditions such as sino-atrial or atrioventricular block. 8. Patients with a history of brittle asthma or obstructive pulmonary disease, requiring regular steroid (inhalers or tablet) for control.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Changes in regional cerebral blood flow (mL/100g/min) measured by two Xenon CT perfusion scans, one performed before the administration of a loading dose of donepezil, and the other after this dose. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The first XeCT scan is performed under general anaesthetic immediately prior to the administration of the first dose of donepezil. It is expected that this would occur within the first 24 hours after enrolment. The second XeCT scan would be performed as soon as possible after the treatment of the participant's aneurysm (but not less than 3 hours after the first XeCT scan (timescale in protocol: 3-24h). |
|
E.5.2 | Secondary end point(s) |
1. Modified Rankin Score at 6 months. 2. Evidence of brain infarction on imaging (CT or MRI) not related to aneurysm occlusion treatment. 3. Delayed clinical neurological deficits. 4. Number of hospital days. 5. Need for endovascular treatment of large vessel spasm
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Modified Rankin Score - 6 months after admission.
All other secondary outcomes would be evaluated during the participant's acute admission for subarachnoid haemorrhage (usually 1-4 weeks). |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | Yes |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 11 |
E.8.9.1 | In the Member State concerned days | 29 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 11 |
E.8.9.2 | In all countries concerned by the trial days | 29 |